Cornelis Melief

Q: What Schools Are Affiliated With Cornelis Melief

Cornelis Melief is affiliated with the following schools: Utrecht University, University of Groningen, University of Zurich, Leiden University

Cornelis Melief's AcademicInfluence.com Rankings

Cornelis Melief

Biology

#4478

World Rank

#6673

Historical Rank

Immunology

#212

World Rank

#221

Historical Rank

biology Degrees

Download Badge

Biology

Cornelis Melief's Degrees

PhD Immunology Leiden University
Doctorate Medicine Leiden University

Why Is Cornelis Melief Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Cornelis Joseph Maria Melief is a globally recognised immunology expert specialising in cancer immunology and immunotherapy, with special focus on therapeutic cancer vaccines. He is Emeritus Professor, former head of the Department of Immunohematology and Blood Transfusion at the Leiden University Medical Center, and Chief Scientific Officer at ISA Therapeutics in Netherlands. He is known for his work in the field of cancer immunology, devising new cancer therapies based on the activation of the patient’s own immune system.

(See a Problem?)

Cornelis Melief's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions (1998) (2961)
B lymphocytes secrete antigen-presenting vesicles (1996) (2928)
Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens (2014) (1612)
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses (2001) (1129)
Dendritic cell immunotherapy: mapping the way (2004) (1012)
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. (2009) (987)
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. (1994) (891)
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells (1993) (851)
CD4+ T cell help in cancer immunology and immunotherapy (2018) (736)
Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors (1998) (664)
Cancer immunology. (2011) (625)
CD4 T Cells and Their Role in Antitumor Immune Responses (1999) (580)
Decreased tumor surveillance in perforin-deficient mice (1996) (568)
Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines (2008) (549)
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy (1999) (545)
Cancer immunotherapy by dendritic cells. (2008) (534)
Vaccines for established cancer: overcoming the challenges posed by immune evasion (2016) (518)
Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 (2002) (454)
A T-cell receptor γ/CD3 complex found on cloned functional lymphocytes (1987) (434)
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. (1995) (432)
Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. (1996) (416)
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. (2009) (387)
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. (2007) (385)
Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine (2008) (380)
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. (1994) (373)
Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors (2001) (373)
Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein (1999) (371)
Classification of current anticancer immunotherapies (2014) (357)
MHC II in Dendritic Cells is Targeted to Lysosomes or T Cell‐Induced Exosomes Via Distinct Multivesicular Body Pathways (2009) (356)
CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. (2003) (351)
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. (1991) (337)
Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine (2001) (328)
Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity (1983) (323)
Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 (2004) (316)
Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity (2008) (310)
Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. (1996) (308)
Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. (1992) (298)
Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. (1999) (298)
Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells (2001) (297)
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical Trial (2019) (296)
Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes (1989) (288)
Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis (2001) (283)
Antigen-Antibody Immune Complexes Empower Dendritic Cells to Efficiently Prime Specific CD8+ CTL Responses In Vivo1 (2002) (272)
Therapeutic cancer vaccines (2021) (262)
Peptide selection by MHC class I molecules (1991) (252)
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses (2010) (245)
Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes (1997) (243)
Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. (1999) (239)
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. (2003) (238)
CD40 stimulation leads to effective therapy of CD40− tumors through induction of strong systemic cytotoxic T lymphocyte immunity (2002) (238)
Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyte–Induced Apoptosis (2001) (236)
CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity1 (2007) (235)
Immature Dendritic Cells Acquire Cd8+Cytotoxic T Lymphocyte Priming Capacity upon Activation by T Helper Cell–Independent or–Dependent Stimuli (2000) (232)
Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. (1993) (229)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma (2009) (228)
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens (2007) (223)
A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. (1996) (221)
Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. (1996) (218)
Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes (1993) (216)
Mini‐review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross‐priming and direct priming? (2003) (209)
Pretransplantation blood transfusion revisited. (1991) (207)
Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. (1996) (205)
Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. (1996) (204)
Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. (2000) (201)
Therapeutic cancer vaccines. (2010) (200)
Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells (1995) (197)
Allele-specific differences in the interaction of MHC class I molecules with transporters associated with antigen processing. (1996) (196)
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction (2020) (194)
Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication1 (2004) (192)
Dendritic cells regulate exposure of MHC class II at their plasma membrane by oligoubiquitination. (2006) (192)
Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer. (1996) (190)
Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. (1995) (185)
Strategies for immunotherapy of cancer. (2000) (184)
Adenoviruses Activate Human Dendritic Cells without Polarization toward a T-Helper Type 1-Inducing Subset (1999) (181)
Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma (2000) (181)
Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors (1995) (179)
Prognostic Value of Tumor-Infiltrating Dendritic Cells in Colorectal Cancer: Role of Maturation Status and Intratumoral Localization (2005) (177)
Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells* (2007) (175)
Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. (1998) (172)
Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. (2002) (171)
Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentation (2008) (169)
Highly Efficient Transduction of Human Monocyte-Derived Dendritic Cells with Subgroup B Fiber-Modified Adenovirus Vectors Enhances Transgene-Encoded Antigen Presentation to Cytotoxic T Cells1 (2001) (166)
Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. (1998) (166)
Natural T‐helper immunity against human papillomavirus type 16 (hpv16) e7–derived peptide epitopes in patients with hpv16‐positive cervical lesions: Identification of 3 human leukocyte antigen class ii–restricted epitopes (2001) (161)
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial (2013) (160)
Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants (2006) (158)
Molecular Mimicry of Human Cytochrome P450 by Hepatitis C Virus at the Level of Cytotoxic T Cell Recognition (1999) (157)
Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer (2009) (157)
Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell–Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects (2013) (157)
Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. (2001) (157)
Human Papillomavirus (HPV) Upregulates the Cellular Deubiquitinase UCHL1 to Suppress the Keratinocyte's Innate Immune Response (2013) (154)
Human Papillomavirus Deregulates the Response of a Cellular Network Comprising of Chemotactic and Proinflammatory Genes (2011) (152)
The Human Vaccines Project: A roadmap for cancer vaccine development (2016) (151)
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T‐cell activation (2013) (149)
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses (2016) (147)
Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC- restricted and MHC-regulated; a model for MHC-disease associations (1986) (147)
Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. (1995) (142)
Adhesion of T and B lymphocytes to extracellular matrix and endothelial cells can be regulated through the beta subunit of VLA (1992) (140)
Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity (2009) (140)
MHC Class I Antigen Processing of an Adenovirus CTL Epitope Is Linked to the Levels of Immunoproteasomes in Infected Cells1 (2000) (138)
Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody (2011) (136)
Proliferation of T gamma cells with killer-cell activity in two patients with neutropenia and recurrent infections. (1980) (136)
Spontaneous tumor rejection by cbl-b–deficient CD8+ T cells (2007) (135)
Differential Influence on Cytotoxic T Lymphocyte Epitope Presentation by Controlled Expression of Either Proteasome Immunosubunits or Pa28 (2000) (133)
Design and development of synthetic peptide vaccines: past, present and future (2007) (131)
Therapeutic vaccination against human papilloma virus induced malignancies. (2011) (130)
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. (2011) (130)
Reduced cell surface expression of HLA-C molecules correlates with restricted peptide binding and stable TAP interaction. (1998) (130)
Antigen Loading of MHC Class I Molecules in the Endocytic Tract (2001) (129)
CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. (1995) (129)
T‐Cell Immunotherapy of Tumors by Adoptive Transfer of Cytotoxic T Lymphocytes and by Vaccination with Minimal Essential Epitopes (1995) (129)
MHC class II compartments and the kinetics of antigen presentation in activated mouse spleen dendritic cells. (1995) (129)
NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. (2008) (128)
Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial (2009) (126)
Ins and Outs of Dendritic Cells (2006) (123)
The rat cim effect: TAP allele-dependent changes in a class I MHC anchor motif and evidence against C-terminal trimming of peptides in the ER. (1996) (123)
Identification of T-cell epitopes for cancer immunotherapy (2007) (122)
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response (2016) (119)
Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. (2005) (118)
Immune Complex-Loaded Dendritic Cells Are Superior to Soluble Immune Complexes as Antitumor Vaccine1 (2006) (114)
Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. (1998) (114)
Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes (2002) (113)
CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. (1998) (113)
Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. (1995) (112)
Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes (2011) (111)
In Vivo Triggering Through 4-1BB Enables Th-Independent Priming of CTL in the Presence of an Intact CD28 Costimulatory Pathway1 (2002) (109)
Abrogation of CTL Epitope Processing by Single Amino Acid Substitution Flanking the C-Terminal Proteasome Cleavage Site1 (2000) (106)
Design and evaluation of antigen-specific vaccination strategies against cancer. (2000) (104)
Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. (1996) (104)
Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. (2006) (103)
Importance of CD4(+) T helper cell responses in tumor immunity. (2000) (103)
p53, a potential target for tumor-directed T cells. (1994) (102)
Peptide loading of empty major histocompatibility complex molecules on RMA‐S cells allows the induction of primary cytotoxic T lymphocyte responses (1991) (102)
Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. (1997) (101)
Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity. (1994) (99)
Differential Kinetics of Antigen-Specific CD4+ and CD8+ T Cell Responses in the Regression of Retrovirus-Induced Sarcomas1 (2002) (99)
An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. (1995) (99)
Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. (1993) (99)
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells. (2016) (98)
Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. (2002) (97)
Analogues of CTL epitopes with improved MHC class‐I binding capacity elicit anti‐melanoma CTL recognizing the wild‐type epitope (1997) (96)
Rapid Peptide Turnover and Inefficient Presentation of Exogenous Antigen Critically Limit the Activation of Self-Reactive CTL by Dendritic Cells1 (2001) (92)
Vaccine-Induced Effector-Memory CD8+ T Cell Responses Predict Therapeutic Efficacy against Tumors (2012) (90)
The role of CD40 in peripheral T cell tolerance and immunity (2000) (90)
A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. (1995) (90)
Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells (2004) (89)
Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA‐DQ and –DP as a restriction element (2008) (87)
Vaccination for treatment and prevention of cancer in animal models. (2006) (87)
Peptide-based cancer vaccines. (1996) (86)
Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates (2014) (86)
HLA and susceptibility to cervical neoplasia. (1999) (86)
Fine specificity of alloimmune cytotoxic T lymphocytes directed against H-2K. A study with Kb mutants (1980) (83)
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients (2016) (82)
Long peptides induce polyfunctional T cells against conserved regions of HIV‐1 with superior breadth to single‐gene vaccines in macaques (2010) (82)
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions (2012) (82)
T cell depletion in transgenic mice carrying a mutant gene for TCR-β (1989) (80)
Longevity of Antigen Presentation and Activation Status of APC Are Decisive Factors in the Balance Between CTL Immunity Versus Tolerance1 (2001) (80)
Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment (2005) (80)
L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. (1998) (79)
Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death (2014) (79)
Reduced human leukocyte antigen expression in advanced‐stage Ewing sarcoma: implications for immune recognition (2009) (77)
Cell‐mediated autoimmunity in patients with Wegener's granulomatosis (WG) (1995) (75)
Abolition of specific immune response defect by immunization with dendritic cells (1985) (75)
An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. (1995) (75)
Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment (2013) (74)
Detection of human papillomavirus type 18 E6 and E7‐specific CD4+ T‐helper 1 immunity in relation to health versus disease (2006) (73)
Thymus dictates major histocompatibility complex (MHC) specificity and immune response gene phenotype of class II MHC-restricted T cells but not of class I MHC-restricted T cells (1984) (73)
Identification of three non‐VNTR MUC1‐derived HLA‐A*0201‐restricted T‐cell epitopes that induce protective anti‐tumor immunity in HLA‐A2/Kb‐transgenic mice (2001) (72)
Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression (2015) (72)
Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. (2003) (72)
Identification of HLA‐A*0201‐restricted CTL epitopes encoded by the tumor‐specific MAGE‐2 gene product (1997) (71)
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention (2020) (71)
Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. (2005) (70)
Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC. (1998) (70)
Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells. (1988) (70)
Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study (2012) (69)
CD27-CD70 Costimulation Controls T Cell Immunity during Acute and Persistent Cytomegalovirus Infection (2013) (68)
Detection and Functional Analysis of CD8+ T Cells Specific for PRAME: a Target for T-Cell Therapy (2006) (68)
Functional properties of T cells in patients with chronic T gamma lymphocytosis and chronic T cell neoplasia. (1982) (68)
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. (2008) (68)
Association between the cellular p53 and the adenovirus 5 E1B‐55kd proteins reduces the oncogenicity of Ad‐transformed cells. (1990) (68)
Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance (2017) (66)
High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. (2000) (66)
p53: A Potential Target Antigen for Immunotherapy of Cancer (2000) (66)
CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. (1998) (64)
Long lasting p53‐specific T cell memory responses in the absence of anti‐p53 antibodies in patients with resected primary colorectal cancer (2001) (64)
Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody (2005) (64)
The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. (2014) (63)
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival (2020) (63)
C3-symmetric peptide scaffolds are functional mimetics of trimeric CD40L (2005) (62)
Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. (1993) (62)
The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation (2015) (62)
Inflammasome-Dependent Induction of Adaptive NK Cell Memory. (2016) (61)
Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. (2001) (61)
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. (2002) (61)
A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. (1999) (60)
Regulation of the cytotoxic T lymphocyte response against Sendai virus analyzed with H-2 mutants. (1983) (59)
Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. (1995) (58)
Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. (2009) (57)
Mutations in the major histocompatibility complex class I antigen‐presenting groove affect both negative and positive selection of T cells (1990) (56)
Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. (2007) (56)
Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). (1997) (56)
Mechanisms of induction of primary virus‐specific cytotoxic T lymphocyte responses (1992) (56)
Distinct regulation and impact of type 1 T‐cell immunity against HPV16 L1, E2 and E6 antigens during HPV16‐induced cervical infection and neoplasia (2006) (55)
Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma (1999) (55)
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer (2012) (54)
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer (2015) (54)
SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated cytotoxicity. (2005) (53)
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. (2013) (53)
Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells. (1998) (53)
Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. (2008) (53)
The detection of circulating human papillomavirus‐specific T cells is associated with improved survival of patients with deeply infiltrating tumors (2011) (52)
Cyclophosphamide enhances anti‐tumor effect of wild‐type p53‐specific CTL (2000) (52)
Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors (2011) (51)
Potential immunogenicity of oncogene and tumor suppressor gene products. (1993) (51)
Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients (2003) (51)
Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy (2019) (51)
Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial (2013) (51)
Immunotherapy for persistent viral infections and associated disease. (2011) (51)
Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. (2010) (50)
Fcγ Receptor IIb Strongly Regulates Fcγ Receptor-Facilitated T Cell Activation by Dendritic Cells (2012) (50)
Induction of a primary human cytotoxic T‐lymphocyte response against a novel conserved epitope in a functional sequence of HIV‐1 reverse transcriptase (1995) (50)
Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. (1999) (50)
Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer (2015) (50)
Lack of correlation between levels of MHC class I antigen and susceptibility to lysis of small cellular lung carcinoma (SCLC) by natural killer cells. (1989) (49)
The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study (2014) (49)
Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin (2000) (49)
Immunization with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. (1993) (48)
Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication (2018) (46)
Human papillomavirus status in young patients with head and neck squamous cell carcinoma (2012) (45)
Differential Expression Regulation of the α and β Subunits of the PA28 Proteasome Activator in Mature Dendritic Cells1 (2005) (45)
Strict peptide length is not required for the induction of cytotoxic T lymphocyte‐mediated antiviral protection by peptide vaccination (1993) (45)
The Tumoricidal Activity of Memory CD8+ T Cells Is Hampered by Persistent Systemic Antigen, but Full Functional Capacity Is Regained in an Antigen-Free Environment1 (2004) (44)
A crucial role of the H-2 D locus in the regulation of both the D- and the K-associated cytotoxic T lymphocyte response against Moloney leukemia virus, demonstrated with two Db mutants. (1982) (44)
Antigen Presentation by an Immature Myeloid Dendritic Cell Line Does Not Cause CTL Deletion In Vivo, but Generates CD8+ Central Memory-Like T Cells That Can Be Rescued for Full Effector Function1 (2005) (44)
Circulating specific antibodies enhance systemic cross‐priming by delivery of complexed antigen to dendritic cells in vivo (2012) (44)
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia (2008) (43)
Peptide Vaccination with an Anchor‐Replaced CTL Epitope Protects Against Human Papillomavirus Type 16‐Induced Tumors Expressing the Wild‐Type Epitope (1998) (42)
Immunocompetence and Malignancy (1975) (42)
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects. (1992) (41)
TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients (2016) (41)
Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies (2011) (40)
Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay. (1995) (40)
Functional properties of neoplastic T cells in adult T cell lymphoma/leukemia patients from the Caribbean. (1984) (40)
The viral context instructs the redundancy of costimulatory pathways in driving CD8+ T cell expansion (2015) (40)
HLA Class II Restricted T-Cell Reactivity to a Developmentally Regulated Antigen Shared by Leukemic Cells and CD34+ Early Progenitor Cells (1997) (39)
Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques (2012) (39)
Intraocular Tumor Antigen Drains Specifically to Submandibular Lymph Nodes, Resulting in an Abortive Cytotoxic T Cell Reaction (2004) (39)
A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes. (1987) (38)
Role of LFA-1 and VLA-4 in the adhesion of cloned normal and LFA-1 (CD11/CD18)-deficient T cells to cultured endothelial cells. Indication for a new adhesion pathway. (1992) (38)
Rejection of Intraocular Tumors by CD4+ T Cells Without Induction of Phthisis1 (2001) (38)
Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model. (1989) (38)
Prediction of the immunogenic potential of frameshift‐mutated antigens in microsatellite instable cancer (2008) (37)
Cryopreservation of cells for immunological typing of non-Hodgkin's lymphomas. (1980) (37)
Magnitude and polarization of P53‐specific T‐helper immunity in connection to leukocyte infiltration of colorectal tumors (2003) (37)
Induction of transplantation tolerance by intravenous injection of allogeneic lymphocytes across an H‐2 class II mismatch. Different mechanisms operate in tolerization across an H‐2 class I vs. H‐2 class II disparity (1990) (37)
Macrophages are vital in spontaneous intraocular tumor eradication. (2006) (36)
Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. (1998) (36)
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes (2006) (36)
CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts. (2005) (36)
Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. (2012) (35)
T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy (2011) (35)
HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS. (1997) (35)
Role of dendritic cells in the regulation of class I restricted cytotoxic T lymphocyte responses. (1988) (34)
Mechanism of inhibition and induction of cytolytic activity in cytotoxic T lymphocytes by CD3 monoclonal antibodies. (1987) (33)
Immune-Escape Markers in Relation to Clinical Outcome of Advanced Melanoma Patients Following Immunotherapy (2014) (33)
Expression of Cellular FLICE Inhibitory Protein, Caspase-8, and Protease Inhibitor-9 in Ewing Sarcoma and Implications for Susceptibility to Cytotoxic Pathways (2007) (33)
Monobenzone‐induced depigmentation: from enzymatic blockade to autoimmunity (2011) (33)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (33)
Effective Melanoma Immunotherapy in Mice by the Skin-Depigmenting Agent Monobenzone and the Adjuvants Imiquimod and CpG (2010) (33)
Dendritic cells in cancer immunotherapy. (2008) (32)
Phenotypic and genotypic analysis of large-cell lymphomas, formerly classified as true histiocytic lymphoma: identification of an unusual group of tumors. (1990) (32)
Successful immunotherapy of an intraocular tumor in mice. (1999) (32)
Dermal histocompatibility and in vitro lymphocyte reactions of three newH-2 mutants (1975) (32)
Revival of the regulatory T cell: new targets for drug development. (2004) (32)
The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. (2002) (30)
Creation of immune ‘stealth’ genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1 (2003) (30)
Rapid enrichment of human papillomavirus (HPV)‐specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer (2005) (30)
Interplay between human papillomaviruses and dendritic cells. (2003) (29)
T-cell immunotherapy of cancer. (1991) (29)
Competition‐Based Cellular Peptide Binding Assay for HLA Class I (2004) (29)
Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancer. (1994) (29)
The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes. (1995) (29)
Characterization of Antigen-Specific Immune Responses Induced by Canarypox Virus Vaccines1 (2007) (28)
N-linked glycan modification on antigen-presenting cells restores an allospecific cytotoxic T cell response (1990) (28)
DC-ATLAS: a systems biology resource to dissect receptor specific signal transduction in dendritic cells (2010) (28)
Anti-Melanoma immunity and local regression of cutaneous metastases in melanoma patients treated with monobenzone and imiquimod; a phase 2 a trial (2018) (28)
Cellular immunity against human papillomavirus associated cervical cancer (1996) (28)
“License to Kill” Reflects Joint Action of CD4 and CD8 T Cells (2013) (28)
Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies. (1990) (28)
N-tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2. (2014) (27)
Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model. (1995) (27)
Cancer: Immune pact with the enemy (2007) (27)
T-chronic lymphocytic leukaemia presenting as primary hypogammaglobulinaemia--evidence of a proliferation of T-suppressor cells. (1982) (27)
Dendritic cells as specialized antigen-presenting cells. (1989) (27)
Enzyme analysis of lymphoproliferative diseases: a useful addition to cell surface phenotyping. (1983) (27)
Colorectal cancer vaccines in clinical trials (2011) (27)
Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells. (1990) (27)
Direct demonstration that cytotoxic T lymphocytes recognize conformational determinants and not primary amino acid sequences (1983) (26)
Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses (2020) (26)
Cancer: Precision T-cell therapy targets tumours (2017) (26)
Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19 (2005) (26)
Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization. (1995) (25)
Allograft tolerance induction in adult mice associated with functional deletion of specific CTL precursors. (1989) (25)
Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis (2016) (24)
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools (2012) (24)
Primary virus-induced lymphomas evade T cell immunity by failure to express viral antigens (1989) (24)
Fine specificity of human HLA-B7-specific cytotoxic T-lymphocyte clones. I. Identification of HLA-B7 subtypes and histotopes of the HLA-B7 cross-reacting group. (1986) (23)
A human monoclonal antibody, produced following in vitro immunization, recognizing an epitope shared by HLA-A2 subtypes and HLA-A28. (1993) (23)
The distinct role of T cell costimulation in antiviral immunity. (2013) (23)
Antigen-specific active immunotherapy for ovarian cancer. (2009) (23)
T-cell regulation of human B-cell activation. A reappraisal of the role of interleukin 2. (1985) (23)
CD40-Mediated Amplification of Local Immunity by Epithelial Cells Is Impaired by HPV (2014) (22)
Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C (2012) (22)
Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. (1996) (22)
Mechanism of skin allograft enhancement across an H‐2 class I mutant difference. Evidence for involvement of veto cells (1988) (22)
Strategies for improved antigen delivery into dendritic cells. (2001) (22)
Tumor rejection antigens and tumor specific cytotoxic T lymphocytes. (1994) (22)
ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response (2022) (22)
Immunological typing of acute lymphoblastic leukaemia. (2009) (22)
Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. (2014) (21)
Antigen-specific active immunotherapy for ovarian cancer. (2014) (21)
Cytotoxic T cell response against lymphoblasts infected with Moloney (Abelson) murine leukemia virus. Methodological aspects and H‐2 requirements (1981) (21)
Individual mice recognize the complex nature of H-2 antigens; unexpected reactions (anti-Kk) in anti-BALB/c-H-2d sera produced in the BALB/c-H-2db mutant. (1979) (21)
Immunotherapeutic strategies for cervical squamous carcinoma. (1999) (21)
DNA/long peptide vaccination against conserved regions of SIV induces partial protection against SIVmac251 challenge (2013) (21)
Tumor-Expressed B 7-H 1 and B 7-DC in Relation to PD-1 + T-Cell Infiltration and Survival of Patients with Cervical Carcinoma (2009) (21)
Nonresponsiveness to the male antigen H-Y in H-2 I-A-mutant B6.C-H-2bm12 is not caused by defective antigen presentation. (1983) (21)
Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: towards synthetic epitope-based vaccines. (2006) (21)
2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation. (2009) (20)
In vivo efficacy of virus-derived peptides and virus-specific cytotoxic T lymphocytes. (1991) (20)
Superior tumor protection induced by a cellular vaccine carrying a tumor-specific T helper epitope by genetic exchange of the class II-associated invariant chain peptide. (2000) (19)
Cancer immunology: Cat and mouse games (2005) (19)
Effective Immunotherapy of Cancer in MUC1-Transgenic Mice Using Clonal Cytotoxic T Lymphocytes Directed Against an Immunodominant MUC1 Epitope (2002) (19)
The current status of therapeutic HPV vaccine. (1996) (18)
Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus. (2011) (18)
Both LFA‐1‐positive and ‐deficient T cell clones require the CD2/LFA‐3 interaction for specific cytolytic activation (1992) (18)
Cancer Therapy : Preclinical Local Activation of CD 8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD 40 Antibody (2011) (17)
Control of immune escaped human papilloma virus is regained after therapeutic vaccination. (2017) (17)
Lymphocytotoxic antibodies produced by H—2 allo-immunisation distinguish between MuLV-positive and -negative substrains of the same H-2 haplotype (1979) (17)
Characterization of two human monoclonal antibodies reactive with HLA-B12 and HLA-B60, respectively, raised by in vitro secondary immunization of peripheral blood lymphocytes. (1993) (17)
Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. (2004) (17)
Lessons from T cell responses to virus induced tumours for cancer eradication in general. (1992) (17)
Polyclonal expansion of T-cell receptor-gamma delta+ T lymphocytes associated with neutropenia and thrombocytopenia. (1992) (17)
Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine. (2012) (17)
Cytotoxic T lymphocytes generated across an I‐Ab mutant difference are directed against a molecule bearing Ia antigens (1981) (17)
Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule (2014) (17)
Specificity and regulation of cytotoxic T-lymphocyte responses analyzed with H-2 mutants. (1983) (16)
Maintenance of Immune Tolerance Depends on Normal Tissue Homeostasis (2005) (16)
K‐cell lymphocytosis/neutropenia syndrome: the neutropenia is not caused by autoimmunity (1986) (16)
New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer. (2015) (16)
1136ONivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer (2017) (16)
Affinity, specificity and T‐cell‐receptor diversity of melanoma‐specific CTL generated in vitro against a single tyrosinase epitope (1997) (15)
Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity. (1994) (15)
Activation or frustration of anti-tumor responses by T-cell-based immune modulation. (1997) (14)
CML typing of serologically identicalH-2 mutants (1977) (14)
Escort service for cross-priming (2005) (14)
Efficient tumor eradication by adoptively transferred cytotoxic T‐cell clones in allogeneic hosts (1996) (14)
Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. (2012) (13)
A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects. (1993) (13)
Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10-producing CD4+ T cells. (2004) (13)
Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses. (2010) (13)
Effective CD8(+) T cell priming and tumor protection by enterotoxin B subunit-conjugated peptides targeted to dendritic cells. (2009) (13)
Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms. (1991) (13)
HBV-Derived Synthetic Long Peptide Can Boost CD4+ and CD8+ T-Cell Responses in Chronic HBV Patients Ex Vivo (2017) (13)
Mutation-specific T cells for immunotherapy of gliomas. (2015) (13)
Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides. (1994) (12)
Local immunomodulation for cancer therapy (2013) (12)
Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C (2012) (12)
Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System (2018) (12)
Peptide specificity of alloreactive CD4 positive T lymphocytes directed against a major histocompatibility complex class I disparity. (1996) (12)
Do epitopes derived from autoantigens display low affinity for MHC class I? (1997) (12)
Differential recognition by human cytotoxic T cell clones of human M1 fibroblasts transfected with an HLA-B7 gene (JY150) suggests the existence of two different HLA-B7 alleles in the cell line JY (HLA-A2,2;B7,7;Cw-,-;DR4,w6). (1988) (12)
T gamma lymphocytosis is clinically non-progressive but immunologically heterogeneous. (1985) (12)
HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells. (1997) (12)
IgG-Mediated Anaphylaxis to a Synthetic Long Peptide Vaccine Containing a B Cell Epitope Can Be Avoided by Slow-Release Formulation (2014) (11)
Targeting the PD-1/PD-L1 Axis in Human Vitiligo (2020) (11)
DC‐induced CD8+ T‐cell response is inhibited by MHC class II‐dependent DX5+CD4+ Treg (2009) (11)
Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses (2018) (11)
Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques (2015) (11)
Immunosurveillance of virus-induced tumors. (1989) (11)
clone recognizing a wild-type p53-derived peptide Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte (1996) (11)
A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection (2022) (11)
Novel insights into the HLA class I immunopeptidome and T-cell immunosurveillance (2017) (10)
Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1. (2015) (10)
Potentiation of a P53-SLP vaccine by cyclophosphamide in ovarian cancer, A single ARM phase II study (2011) (10)
Design of TLR2-ligand-synthetic long peptide conjugates for therapeutic vaccination of chronic HBV patients. (2020) (9)
BCR‐ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation (1998) (9)
Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma (2018) (9)
A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation. (1992) (9)
ANALYSIS OF H-2 MUTANTS. CELL MEDIATED REACTIVITY OF THE H-2be VARIANT AND FOUR Z-1 LOCUS MUTANTS (1976) (9)
Variable MLC stimulatory capacity of neoplastic B and non-B/non-T lymphocytes expressing HLA-DR antigens. (2008) (9)
Smart delivery of vaccines (2018) (9)
Induction of p 53-Specific Immunity by a p 53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer (2009) (9)
Immunotherapy of cancer through targeting of the p53 tumor antigen. (2002) (9)
Enhancement of proliferation and downregulation of TRAIL expression on CD8+ T cells by IL‐21 (2010) (8)
Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape. (1995) (8)
Cytotoxic T lymphocyte priming versus cytotoxic T lymphocyte tolerance induction: a delicate balancing act involving dendritic cells. (1999) (8)
Structured reporting of T cell assay results. (2013) (8)
Regulatory effect of interleukin-4 (IL-4) on the expression and function of lymphocyte adhesion receptors involved in IL-2-induced cell aggregation. (1993) (8)
A phase I study in patients with a human papillomavirus type 16 positive oropharyngeal tumor treated with second generation synthetic long peptide vaccine conjugated to a defined adjuvant. (2016) (8)
Dendritic Cells and Antigen Presentation in the Regulation of Cytotoxic T Lymphocyte Responses against Viruses and Transplantation Antigens (1988) (8)
Recognition of H-2Kb mutant target cells by Moloney virus-specific cytotoxic T lymphocytes from bm13 (H-2Db mutant) mice. I. Full recognition of Kbm11 by Kb-restricted CTL. (1984) (7)
Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival. (2017) (7)
Reconstitution of recombinant interleukin-2 (rIL-2): a comparative study of various rIL-2 muteins. (1993) (7)
Transfusion-induced skin allograft enhancement across an H-2 class-I mismatch is caused by a clonal deletion of donor-specific cytotoxic T-lymphocyte precursors within the allograft. (1989) (6)
In vivo detection of fluorescent tumor-specific cytotoxic T cell clones. (1993) (6)
BCR-ABL Directed Immunotherapy: A Virtual Reality? (2000) (6)
Functional and molecular characterization of B cell line derived interleukin-1 alpha. (1989) (6)
Enhancement of the antibody-dependent cellular cytotoxicity of human peripheral blood lymphocytes with interleukin-2 and interferon α (2005) (6)
Recognition of H-2Kb mutant target cells by Moloney virus-specific cytotoxic T lymphocytes from bm13 (H-2Db-mutant) mice. II. Relationship of Kbm3 and Kbm11 in restriction specificities and allodeterminants. (1984) (6)
Evaluation of the high-pressure extrusion technique as a method for sizing plasmid DNA-containing cationic liposomes (2011) (6)
Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting (2013) (6)
Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer. (2017) (5)
Editorial: Novel Strategies for Anti-Tumor Vaccines (2020) (5)
Immunobiology of the expanded T cells in T-cell leukemia and T-gamma lymphocytosis. (1986) (5)
Separate roles for antigen recognition and lymph node inflammation in CD8+ memory T cell formation. (2010) (5)
Peptide-Based Therapeutic Cancer Vaccines (2018) (5)
Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells (2021) (5)
Functional and ultrastructural aspects of antigen processing by dendritic cells. (1995) (5)
Least Four Unrelated + CD 4 Is Processed and Presented to HIV-Specific Epitope in HIV-1 Reverse Transcriptase That Identification of a Conserved Universal Th (1998) (5)
Protective T-cell responses against tumours. (1998) (4)
Efficacy of cytotoxic T lymphocytes against virus-induced tumors. (1990) (4)
T-Cell Immunotherapy against Mutant KRAS for Pancreatic Cancer. (2022) (4)
Target specificity of cytotoxic t cells directed against h-2l. Abstr. (1979) (4)
IFN‐γ‐induced PD‐L1 expression on human melanocytes is impaired in vitiligo (2021) (4)
Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy (2011) (4)
Different requirements for the regulation of transplantation tolerance induction for allogeneic versus xenogeneic major histocompatibility complex antigens. (1990) (4)
Altered expression of cellular genes in adenovirus-transformed cells (1983) (4)
Thymic immune response gene function in radiation chimeras reconstituted with purified hemopoietic stem cells (1987) (4)
Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide. (1996) (4)
B lymphocyte activation and differentiation (1988) (3)
4 Generation and Characterization of Killer Cells (1998) (3)
Prediction the clinical outcomes of cancer patients after peptide vaccination. (2019) (3)
Corrigendum to “Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists” [Vaccine 2007;25(8):1379–89] (2007) (3)
Synergy between chemotherapy and cancer vaccination (2015) (3)
Idiotypic immunoglobulin secretion by human B cell non-Hodgkin's lymphomas is related to the expression of the interleukin-2 receptor. (1988) (3)
CD 80-Transfected Acute Myeloid Leukemia Cells Induce Primary Allogeneic (1998) (3)
A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in a lack of antigen presentation (1997) (3)
Selective activation of oxygen-deprived tumor-infiltrating lymphocytes through local intratumoral delivery of CD137 monoclonal antibodies. (2012) (3)
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer (2012) (3)
Production of mouse monoclonal antibodies for the analysis of idiotypes in serum of patients with chronic lymphatic leukaemia (1988) (3)
Scientific contributions toward successful cancer immunotherapy in The Netherlands. (2014) (2)
Remission of monoclonal chronic T-cell expansion associated with severe anemia. (1991) (2)
Special Review: The future of Immunotherapy (2020) (2)
Mechanisms of transplantation tolerance: do anti-idiotypic antibodies play a role? (1991) (2)
Additional file 8 (2012) (2)
Chemical synthesis of the HPV16 E7 protein (2006) (2)
Abstract 2938: Synergistic effects of properly timed HPV16 synthetic long peptide vaccination during standard carboplatin-paclitaxel chemotherapy in animals and in patients with metastatic cervical carcinoma (2014) (2)
Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides. (2021) (2)
Processing of exogenous protein antigen by murine dendritic cells for presentation to cytotoxic T lymphocytes. (1997) (2)
Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer (2022) (2)
T-cell immunity against tumors, a delicate balancing act involving dendritic cells (1999) (2)
as Antitumor Vaccine Are Superior to Soluble Immune Complexes Immune Complex-Loaded Dendritic Cells (2013) (2)
Prospects of T-cell immunotherapy for cancer by peptide vaccination. (1993) (2)
Alternative splicing in the mouse H-2kdgene is not necessary for the classical Kd antigen function (2004) (1)
Human papillomavirus (HPV) downregulates the expression of IFITM1 to resist the anti- proliferative effects of IFNγ and TNFα (2016) (1)
T-Cell Repertoire Tuning by the MHC in Protection Against Lethal Virus Infection and in Rejection of H-Y Disparate Skin Grafts (1986) (1)
Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16 (2023) (1)
T-cell-mediated immunotherapy of cancer (2004) (1)
Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16 (2008) (1)
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions (2022) (1)
Binding and Stable TAP Interaction Molecules Correlates with Restricted Peptide Reduced Cell Surface Expression of HLA-C (1997) (1)
C-Terminal Proteasome Cleavage Site Single Amino Acid Substitution Flanking the Abrogation of CTL Epitope Processing by (2000) (1)
Genetic Control of T-Cell and NK-Cell Protection Against Lethal Sendai Virus Infection (1987) (1)
PRAME: A target antigen for immunotherapy in Ewing’s sarcoma (2005) (1)
Reply to the letter from Janssen et al (1994) (1)
Mechanism of superior cross-presentation of synthetic long peptides in comparison with protein for therapeutic cancer vaccination (2012) (1)
Abstract CT002: A strong HPV-specific T-cell response after chemo-immunotherapy for advanced cervical cancer is associated with prolonged survival (2019) (1)
T cells in patients with chronic Tγ lymphocytosis: Morphology, cytochemistry, ultrastructure and immunological characteristics (1985) (1)
XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) (2012) (1)
Vaccination with recombinant adenoviruses encoding tumor-derived CTL-epitopes in a string-of-bead fashion induces protective anti-tumor immunity (1997) (1)
Abstract A001: Tumor-specific mutant antigens in cancer immunotherapy (2016) (1)
Mutations in H-2Kb influence the specificity of alloreactive effector cells included in the repertoire of H-2Db-restricted cytotoxic T lymphocytes against Moloney leukemia virus (2004) (1)
T-Cell and NK-Mediated Surveillance of Cancer (1998) (1)
CD4+ T Cells, IFN and Macrophages Play an Important Role in the Spontaneous Eradication of an Intraocular Tumor (2003) (0)
CD40 binding antibody and ctl peptide for treatment of tumors (1999) (0)
Peptides from human papilloma virus for use in compositions for the induction of human T-cell response (1993) (0)
Avoided by Peptide Presentation on Dendritic CTL Tolerization After Peptide Vaccination Is Enhancement of Tumor Outgrowth Through (1998) (0)
Immunity Versus Tolerance Factors in the Balance Between CTL Activation Status of APC Are Decisive Longevity of Antigen Presentation and (2001) (0)
T cell responses against tumor antigen PRAME (2001) (0)
Predict Therapeutic Efficacy T + Vaccine-Induced Effector-Memory CD 8 (2012) (0)
Mode of action and exploitation of 4-1BB-dependent CTL-triggering in anti-tumor immunity (2002) (0)
Eradication of an intraocular tumor by tumor-specific cytotoxic T lymphocytes (1997) (0)
CTL-mediated immunity against human papillomavirus type 16 E7-encoded epitopes presented by HLA-A2 (1997) (0)
Precision guiding of cytolytic T-lymphocyte responses (2004) (0)
Immunotherapy of Cancer by Vaccination with Long Synthetic Peptides (2009) (0)
An immunodominant CTL epitope expressed by in vitro transformed cells is derived from plasmid vector backbone sequences (1997) (0)
Safety in numbers. (2005) (0)
Peptides of human p53 protein for use in human cytotoxic T cell response inducing compositions, and human p53 protein-specific T-lymphocytes (1993) (0)
T cell differentiation and function. (1989) (0)
Boosting of Replication Competent NYVAC Primed HIV-1-Specific T-Cell Responses by HIV Synthetic Long Peptides (SLP) (2011) (0)
Analysis and exploitation of p53-specific anti-tumor T cell immunity (2002) (0)
Systemic Inflammatory Response Syndrome (SIRS) After Gp100 Peptide Vaccination for Intraocular Melanoma (2009) (0)
Cellular immune responses against melanoma cells (1988) (0)
HLA-B57 restricted CTL and long-term survival in HIV-1 infection (1997) (0)
Induction of melanoma-reactive CTL in HLA-A*0201/Kb transgenic mice by vaccination with peptides derived from MAGE-2 and MART-1 (1997) (0)
1181 Therapeutic vaccines consisting of cancer germline antigen-based synthetic long peptides are immunogenic in human hepatocellular carcinoma patients (2022) (0)
Tumor Antigens, Viral Origin (2016) (0)
Cellular Immunotherapy — Towards Direct DC Activation for Licence to Kill (2003) (0)
Novel insights into the HLA class I immunopeptidome and T-cell immunosurveillance (2017) (0)
CD40 binding molecules and CTL Peptides for the treatment of tumors (1999) (0)
T-CELL AND NK-MEDIATED SURVEILLANCE (1998) (0)
[A lymphoproliferative disorder of T-cell origin with appearances of chronic lymphatic leukemia]. (1979) (0)
Book Review Immunology of HIV Infection Edited by Sudhir Gupta. 612 pp., illustrated. New York, Plenum, 1996. $95. 0-306-45255-3 (1997) (0)
Abstract PL04-04: Synthetic long peptide vaccines against established disease caused by high-risk human papillomavirus. (2011) (0)
lymphoma/leukemia patients from the Caribbean Functional properties of neoplastic T cells in adult T cell (2011) (0)
Abstract CN01-03: Immunotherapy of established lesions caused by high-risk HPV (2010) (0)
VaccinesResponses Induced by Canarypox Virus Characterization of Antigen-Specific Immune (2007) (0)
Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C (2012) (0)
Regression of Retrovirus-Induced Sarcomas T Cell Responses in the + and CD 8 + Differential Kinetics of Antigen-Specific CD 4 (2002) (0)
The BCR-ABL Oncoprotein and Immunological Targeting - Vaccination for Tumor Prevention and Therapy (2000) (0)
Relevance of proteasome-independent CTL epitopes for anti-cancer immunity and identification of responsible processing enzymes (2005) (0)
Detailed phenotypic characterization of tumor-infiltrating lymphocytes in colorectal cancer patients and correlations with systemic P 53 T cell reactivity (2008) (0)
Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer? (2022) (0)
HPV16 LONG PEPTIDE VACCINE IS SAFE AND INDUCES STRONG TYPE 1 T-CELL IMMUNITY IN PATIENTS WITH END-STAGE CERVICAL CANCER (2004) (0)
Interleukin-2 and tumour eradication by cytotoxic T lymphocytes (1993) (0)
228 Antigen specific active immunotherapy for ovarian cancer (2009) (0)
Precision guiding of cytolytic T-lymphocyte responses in cancer immunotherapy (2005) (0)
Generation of a p53 TCR-tg mouse model (2008) (0)
longer peptides of 22-45 amino acid residues that induce and / or enhance the specific immune responses to antigens (2001) (0)
VaccinesInduced by Canarypox Virus Characterization of Antigen-Specific Immune (2013) (0)
7 Immunotherapy of High Risk HPV Infections (2012) (0)
Immunomodulation with monoclonal antibodies is a powerful new approach to anticancer immunotherapy. Recently, several antibody-based therapies have shown promising results in pre-clinical and clinical investigations, leading to the approval by the US FDA of a cytotoxic T lymphocyte-associated protei (2013) (0)
100 INVITED Progress with cervix cancer vaccines. The end in sight (2007) (0)
Antibody-antigen immune complexes as vaccine vehicles for immune therapy of cancer (2004) (0)
T cell-mediated immunotherapy in Ewing's sarcoma with a focus on tumor antigen PRAME (2003) (0)
Exosomes isolated from a murine B cell line present antigen to an MHC class II restricted T cell hybridoma (1997) (0)
Full Functional Capacity Is Cells Is Hampered by Persistent Systemic T + The Tumoricidal Activity of Memory CD 8 (2004) (0)
CD4+ T cell help in cancer immunology and immunotherapy (2018) (0)
Cancer vaccines 1 (2015) (0)
cytotoxicity SPI-CI and SPI-6 cooperate in the protection from effector cell-mediated (2013) (0)
Isolated, MAGE-2 derived tumorafstødelsesantigenpræcurserpeptider and use thereof (1995) (0)
P17-23. Enhanced expression of HIV antigens and improved antigen presentation after infection with replication competent attenuated vaccinia virus in vitro (2009) (0)
Synergy of therapeutic vaccination against HPV16 oncogenic proteins and standard chemotherapeutics (2014) (0)
Natural T cell response against HPV16 and development of optimal peptide based vaccine (2001) (0)
16 Induction of objective clinical responses by immunotherapy with synthetic long peptides in patients with high grade HPV16-induced premalignant vulva lesions (2010) (0)
Levels of Immunoproteasomes in Infected Adenovirus CTL Epitope Is Linked to the MHC Class I Antigen Processing of an (2000) (0)
Abstract IA26: Combination immunotherapy of cancer caused by human papilloma virus (2019) (0)
Immunotherapy in ovarian cancer patients; involvement and manipulation of regulatory T cells. (2007) (0)
Cancer vaccines 2 (2015) (0)
Timed anti-tumor vaccination during chemotherapy induces strong T-cell immunity and prolonged survival of late stage cervical cancer patients (2019) (0)
Modulation of anti-tumor immune responses by peptide vaccination (1997) (0)
Effectiveness and Side-Effects of Slow-Release Systems in CD40 agonistic Antibody Immunotherapy of Cancer. Chapter (2012) (0)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (0)
OriginMBL-2 Lymphomas Reveals Their Common Epitope Presented by RMA, EL-4, and Identification of a Novel Tumor-Specific CTL (2000) (0)
Imprinting of tumor-specific CD8+ T-cell effector function by dendritic cells and its subversion by tumors (2004) (0)
Immunization with HPV16 virus-like particles protects mice against a challenge with HPV16-induced tumor cells (1997) (0)
Down-Regulatory Role of CD8 Molecules in CD2 MAb and CD3 MAb Induced Nonspecific Cytotoxicity of Cytotoxic T Lymphocyte Clones (1989) (0)
Tumor regression and auto- immunity induced by immuno- therapeutic modalities targeting carcinoembryonic antigen (2006) (0)
0433: Hpv16 Long Peptide Vaccination in Hpv Related Disease: Safety, Immunogenicity and Clinical Efficacy (2006) (0)
breakpoint peptide cells elicited by primary in vitro immunization with a BCR-ABL Recognition of BCR-ABL positive leukemic blasts by human CD4+ T (2011) (0)
Pathway Presence of an Intact CD 28 Costimulatory Th-Independent Priming of CTL in the In Vivo Triggering Through 4-1 BB Enables Mittler (2002) (0)
The consequenses of immuno- and constitutive proteasome expression for tumor-specific CTL-priming and tolerance (2002) (0)
Treatment for anogenital intraepithelial neoplasias induced by HPV. (2006) (0)
Serotyping of mulv positive b10.a V+ and negative b10.a V- substrains. Abstr. (1979) (0)
Abstract IA02: Selection of cancer antigens and conditions for success of immunotherapy of cancer involving vaccination (2016) (0)
Integrated analysis of melanoma-T cell interactions in situ; relevance for immunotherapy (2006) (0)
Analysis of the effect of positive selection on the T cell response against MoLV-induced tumors (1997) (0)
CTL induction antitumor immunity through the live trigger bb 4-1 and / or CD 40. (2003) (0)
Eradication CTL to Cause Tumor + Licenses CD 8 Cross-Present Tumor-Derived Antigen Activation of Dendritic Cells (2004) (0)
H-2 class I mutants utilize novel restriction specificities in the trinitrophenyl-specific cytotoxic T-lymphocyte response. (1985) (0)
New technology to improve vaccines for immunotherapy of cancer: antibody-mediated targeting of synthetic peptide constructs (2009) (0)
Conference scene: Immune signatures in the tumor and beyond. (2012) (0)
Uveal Melanoma Targeting gp 100 Adoptive T Cell Immunotherapy of Human Rienk Offringa (2000) (0)
Subversion of immune responses (1993) (0)
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial (2013) (0)
Probing the T-Cell Repertoire (1985) (0)
Treatment of HPV positive penile and cervical cancer by induction of HPV E7-specific T cell immunity through DNA vaccination (2006) (0)
complex from the precursors of MAGE tumor-derived single abstossungsantigen peptede, the HLA-A2 molecules (1995) (0)
Formation ofimmune-complexes by a defined linear tetanus toxin-derived B cell epitope boosts human T cell responses to long peptides : ICs boost specific-T cells (2017) (0)
TLR ligand-peptide conjugates as optimal vaccine vehicles for specific immunotherapy of HPV16-induced lesions (2007) (0)
derived from MAGE-kasvainhyljintäantigeeniprekursoreista isolated peptides which complex with HLA-A2 molecules (1996) (0)
Distinct uptake mechanisms but similar intracellular processing of two different TLR-peptide conjugates in Dendritic Cells (2007) (0)
HPV16+ CERVICAL CANCER IS ASSOCIATED WITH FAILURE OF A PRO-INFLAMMATORY CD4+ T-CELL RESPONSE AGAINST E2 AND E6; IMPLICATIONS FOR IMMUNOTHERAPY (2004) (0)
Preclinical and clinical experience with peptide-based vaccines against HPV16-induced tumors (1997) (0)
The role of serpin protease in the modulation and efficacy of anti-tumor T-cell responses (2001) (0)
Abstract 2494: Vaccine-induced TNF alpha producing T cells synergize with cisplatin in tumor eradication (2015) (0)
Author response: The viral context instructs the redundancy of costimulatory pathways in driving CD8+ T cell expansion (2015) (0)
Human papillomavirus peptides applicable in the compositions to induce a reaction of T lymphocytes in man. (1993) (0)
Pam3cys-like lipopeptide adjuvant compound in a vaccine composition (2012) (0)
Fine Characterization of the HPVI6 E7 49-57 Tumor Protective Cytotoxic T Cell Epitope “Rahynivtf” (1994) (0)
T helper cell mediated immunity against retrovirus-induced lymphoma (2001) (0)
Precision control of white corpuscles for cancer immunotherapy (2005) (0)
CD4+ and DC requirements for optimal CD8+ CTL induction against tumors (2001) (0)
The HPV16 E7 peptide based vaccine trial in end stage cervical carcinoma: An interim report (1997) (0)
Humant like peptides of the papillomavirus Foer anvaendning The compositions som i inducerar human T-cellsvar (1994) (0)
Reflections on Cancer Vaccines (2014) (0)
Dendritic Cells Limit the Activation of Self-Reactive CTL by Presentation of Exogenous Antigen Critically Rapid Peptide Turnover and Inefficient (2001) (0)
Control of Cytotoxic T-Lymphocyte Responses By Class-I and Class-II H-2 Molecules, Studied with H-2 Mutants (1983) (0)
The Promise of T Cell Immunotherapy of Cancer (1991) (0)
Optimized peptide-based therapeutic vaccines against HPV16+ cancers incorporating advanced antigen delivery strategies and moleculary defined adjuvants (2003) (0)
A method for selecting and producing T cell peptide epitopes and vaccines containing these selected epitopes (1997) (0)
Transcriptional control of the MHC class II transactivator (CIITA): the key regulator of MHC class II mediated antigen presentation (2000) (0)
A phase Istudy ofprolonged continuous infusion oflowdoserecombinant interleukin-2 inmelanoma andrenal cellcancer.PartI:clinical aspects (1992) (0)
Scientific contributions toward successful cancer immunotherapy in (2014) (0)
Reticulum of Immunizing Cells Antigenic Peptides in the Endoplasmic Responses In Vivo Does Not Require Cutting Edge: Cross-Priming of CTL (1998) (0)
Targeting of cytotoxic T cells against leukemic B cells by bispecific antibody (aCD3 x aCD19) does not distract the T cell from its primary target. (1997) (0)
Antigens From Intraocular Tumors Drain Specifically Into Submandibular Lymph Nodes (2002) (0)
Vaccination Strategies to Induce T-Cell Immunity Against Tumours (1997) (0)
Uveal Melanoma Targeting gp100 Adoptive T Cell Immunotherapy of Human (2000) (0)
Breaking of tolerance in a pre-clinical model for CTL-mediated immunotherapy of melanoma (2001) (0)
Efficient direct priming of peptide-specific antitumor CTL following single immunization with a B7.1+ antigen-presenting cell vaccine (1997) (0)
From the Department of Tumor hnmunology , Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical (0)
Correction: Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C (2012) (0)
The role of T cell immune response, directed against tumour-associated antigens of viral or cellular origin, in the prevention and eradication of tumours (2002) (0)
Migration or evasion (2010) (0)
Slow Release and Local Delivery of CTLA-4 blocking Antibody induces Tumor Eradication without Toxicity and is Dependent on CD8+ T cells (2012) (0)
Isolated peptides derived from the MAGE-tumorafstødelsesantigenprækursorer which complexes with HLA-A2 molecules (1995) (0)
Antigen Storage Compartments in Mature Dendritic Cells Facilitate Prolonged CTL Cross- Priming Capacity (2010) (0)
8.8-01 Transfusion-induced immunosuppression across different MHC barriers in mouse and man (1989) (0)
Rescued for Full Effector Function Central Memory-Like T Cells That Can Be + CTL Deletion In Vivo, but Generates CD8 Myeloid Dendritic Cell Line Does Not Cause Antigen Presentation by an Immature (2005) (0)
Peptides Eradicated Following Vaccination with Long 16-Expressing Tumors Are Effectively Established Human Papillomavirus Type (2002) (0)
Immunogenetics: Safety in numbers (2005) (0)
Abstract 1693: T cell responses to peptide-epitopes can be boosted by immune complexes of circulating anti-tetanus antibodies (2017) (0)
The MHC expression of dendritic cells from mouse spleen isolated by centrifugal elutriation is upregulated during short term culture. (1993) (0)
Abstract SY27-01: Synthetic vaccine for immunotherapy of high risk HPV infections. (2013) (0)

This paper list is powered by the following services:

Other Resources About Cornelis Melief

en.wikipedia.org

What Schools Are Affiliated With Cornelis Melief?

Cornelis Melief is affiliated with the following schools:

Cornelis Melief's Academic­Influence.com Rankings